Tolbutamide + Midazolam + Pexidartinib

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drug Interaction Potential

Conditions

Drug Interaction Potential

Trial Timeline

Feb 26, 2018 โ†’ Apr 16, 2021

About Tolbutamide + Midazolam + Pexidartinib

Tolbutamide + Midazolam + Pexidartinib is a phase 1 stage product being developed by Daiichi Sankyo for Drug Interaction Potential. The current trial status is completed. This product is registered under clinical trial identifier NCT03291288. Target conditions include Drug Interaction Potential.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03291288Phase 1Completed